MedTrace Logo

A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults

NCT07749651 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-08-06

No results posted yet for this study

Summary

A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults

Conditions

  • Cutaneous Lupus Erythematosus(CLE)

Interventions

DRUG

SHR-7012 injection ; placebo

A single subcutaneous injection of Dose1 SHR-7012 injection or placebo was administered

DRUG

SHR-7012 injection ; placebo

A single subcutaneous injection of Dose2 SHR-7012 injection or placebo was administered

DRUG

SHR-7012 injection ; placebo

A single subcutaneous injection of Dose3 SHR-7012 injection or placebo was administered

DRUG

SHR-7012 injection ; placebo

A single subcutaneous injection of Dose4 SHR-7012 injection or placebo was administered

DRUG

SHR-7012 injection ; placebo ;

A single subcutaneous injection of Dose5 SHR-7012 injection or placebo was administered

Sponsors & Collaborators

  • Guangdong Hengrui Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-04-30
Completion
2027-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07749651 on ClinicalTrials.gov